This may again be related to ellagitannin interactions, as suggested by Petit et al
Key differences between cagrilintide and semaglutide Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways, complementary effects Gastric emptying: Cagrilintide: Very strong effect (dramatic slowing) Semaglutide: Moderate effect Combined: Maximum slowing Appetite suppression: Cagrilintide: Works via amylin/calcitonin receptors Semaglutide: Works via GLP-1 receptors in brain Combined: Dual-pathway suppression Side effects: Cagrilintide: More nausea/GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Combined: Higher side effect risk but manageable Approval status: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved CagriSema combination: Phase 3 trials Weight loss monotherapy: Cagrilintide alone: 10-12% body weight loss Semaglutide alone: 10-15% body weight loss Combined: 15-25% body weight loss Why combining cagrilintide and semaglutide works synergistically The combination targets weight loss through multiple pathways
Proc Am Soc Clin Oncol 20 : 300 Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J (2005) A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer
Lebensdekade mit Diabetes mellitus Typ 1 Young Hee Lee-Barkey, Bernd Stratmann, Diethelm Tschpe Der Diabetologe.2022
